Replimune Group, Inc. (NASDAQ:REPL) Holdings Raised by LMR Partners LLP

LMR Partners LLP increased its stake in Replimune Group, Inc. (NASDAQ:REPL) by 145.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 82,479 shares of the company’s stock after purchasing an additional 48,920 shares during the quarter. LMR Partners LLP’s holdings in Replimune Group were worth $904,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Nisa Investment Advisors LLC lifted its stake in Replimune Group by 10,304.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after buying an additional 4,946 shares in the last quarter. Point72 DIFC Ltd purchased a new stake in shares of Replimune Group in the 2nd quarter valued at approximately $57,000. Arizona State Retirement System purchased a new position in Replimune Group during the 2nd quarter worth approximately $108,000. Quest Partners LLC grew its position in Replimune Group by 30.4% during the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after purchasing an additional 3,150 shares in the last quarter. Finally, Russell Investments Group Ltd. purchased a new position in Replimune Group during the 1st quarter worth approximately $140,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Roth Mkm started coverage on Replimune Group in a research report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 target price for the company. Roth Capital raised Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Replimune Group in a research report on Tuesday, November 12th. Finally, JPMorgan Chase & Co. raised their price target on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $16.80.

Replimune Group Stock Performance

Shares of REPL stock opened at $10.95 on Wednesday. Replimune Group, Inc. has a fifty-two week low of $4.92 and a fifty-two week high of $12.97. The stock’s 50-day moving average is $11.47 and its two-hundred day moving average is $9.62. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. The firm has a market cap of $749.20 million, a P/E ratio of -3.59 and a beta of 1.19.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. Analysts predict that Replimune Group, Inc. will post -3.02 earnings per share for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.